Treatment of [Cp*Ru(NO)Cl 2 ] (Cp* ) η 5 -C 5 Me 5 ) with NaQAr or LiQAr (Q ) S, Se, Te; Ar ) C 6 F 4 H or Ph) affords [Cp*Ru(NO)(QAr) 2 ]. Interactions of [Cp*Ru(NO)(SC 6 F 4 H) 2 ] with PR 3 (R ) Ph or Me) give [Cp*Ru(PR 3 ) 2 (SC 6 F 4 H)] via phosphoraminate intermediates. The crystal structures of [Cp*Ru(NO)(SC 6 F 4 H) 2 ] and [Cp*Ru(PMe 3 ) 2 (SC 6 F 4 H)] have been determined. Treatment of [Cp*Ru(MeCN) 3 ][PF 6 ] with HN[SeP(i-Pr) 2 ] 2 affords a novel Cp*Ru(IV) complex, [Cp*Ru{η 2 -Se 2 P(i-Pr) 2 }{η 2 -SeP(i-Pr) 2 }][PF 6 ], which has been characterized by X-ray crystallography.